Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells

Nature Genetics

Volumn 12, Issue 2, 1996, Pages 144-148

  Bollag, Gideon ^a   Clapp, D Wade ^b   Shih, Shane ^c   Adler, Felix ^d   Zhang, You Yan ^b   Thompson, Patricia ^d   Lange, Beverly J ^e   Freedman, Melvin H ^f   McCormick, Frank ^a   Jacks, Tyler ^c   Shannon, Kevin ^d  

^a ONYX PHARMACEUTICALS   (United States)

^b INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^f HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; NEUROFIBROMIN; RAS PROTEIN;

ALLELE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER SUSCEPTIBILITY; CELL GROWTH; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL; MOUSE; NEUROFIBROMATOSIS; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL DIVISION; CELLS, CULTURED; CHILD; GENES, NEUROFIBROMATOSIS 1; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; GTPASE-ACTIVATING PROTEINS; GUANOSINE TRIPHOSPHATE; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MICE; NEUROFIBROMATOSIS 1; NEUROFIBROMIN 1; PROTEINS; RAS GTPASE-ACTIVATING PROTEINS; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 9044251606     PISSN: 10614036     EISSN: None     Source Type: Journal    
DOI: 10.1038/ng0296-144     Document Type: Article

References (44)

1. Riccardi, V.M. & Eichner, J.E. Neurofibromatosis (Johns Hopkins University Press, Baltimore, USA, 1986).
2. Bader, J.L. & Miller, R.W. Neurofibromatosis and childhood leukemia. J. Pediat. 92, 925-929 (1978).
3. Shannon, K.M. et al. Monosomy 7 myeloproliferative disease in children with neurofibromatosis, type 1: epidemiology and molecular analysis. Blood 79, 1311-1318 (1992).
4. Gadner, H. & Haas, O.A. Experience in pediatric myelodysplastic syndromes. Hemat. Clin. N.A. 6, 655-672 (1992).
5. Skuse, G.R., Kosciolek, B.A. & Rowley, P.T. Molecular genetic analysis of tumors in von Recklinghausen neurofibromatosis: loss of heterozygosity for chromosome 17. Genes Chrom. Cancer 1, 36-41, (1989).
6. Menon, A.G. et al. Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc. Natl. Acad. Sci. USA 87, 5435-5439 (1990).
7. Glover, T.W. et al. Molecular and cytogenetic analysis of tumors in von Recklinghausen neurofibromatosis. Genes Chrom. Cancer 3, 62-70 (1991).
8. Xu, W. et al. Loss of alleles in pheochromocytomas from patients with type 1 neurofibromatosis. Genes Chrom. Cancer 4, 337-341 (1992).
9. Jacks, T. et al. Tumorigenic and developmental consequences of a targeted Nf1 mutation in the mouse. Nature Genet 7, 353-361 (1994).
10. Bourne, H.R., Sanders, D.A. & McCormick, F. The GTPase superfamily: a conserved switch for diverse cell functions. Nature 348, 125-132 (1990).
11. Bourne, H.R., Sanders, O.A. & McCormick, F. The GTPase superfamily: conserved structure and molecular mechanism. Nature 349, 117-127 (1991).
12. Hall, A. Signal transduction through small GTPases - a tale of two GAPs. Cell 88, 389-391. (1992).
13. Boguski, M. & McCormick, F. Proteins regulating Ras and its relatives. Nature 366, 643-653 (1993).
14. Basu, T.N. et al. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 356, 713-715 (1992).
15. ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 69, 265-273 (1992).
16. The, I. et al. Neurofibromatosis type 1 gene mutations in neuroblastoma. Nature Genet. 3, 62-66, (1993).
17. Andersen, L.B. et al. Mutations in the neurofibromatosis 1 gene in sporadic malignant melanoma cell lines. Nature Genet. 3, 118-121 (1993).
18. Johnson, M.R., Look, A.T., DeClue, J.E., Valentine, M.B. & Lowy, D.R. Inactivation of the NF1 gene in human melanoma and neuroblastoma cell lines without impaired regulation of GTP-Ras. Proc. Natl. Acad. Sci. USA 90, 5539-5545 (1993).
19. Rodenhuis, S. Ras and human tumors. Semin. Cancer Biol. 3, 241-247 (1992).
20. Noda, M., Ko, M. & Ogura, A. Sarcoma viruses carrying the ras oncogene activate differentiation-associated properties of a neuronal cell line. Nature 318, 73-75 (1985).
21. Bar-Sagi, D. & Feramisco, J.R. Microinjection of the ras oncogene protein into PC12 cells induces morphological differentiation. Cell 42, 841-848 (1985).
22. Ridley, A.J., Paterson, H.F., Noble, M. & Land, H. ras-mediated cell cycle arrest is altered by nuclear oncogenes to induce Schwann cell transformation. EMBO J. 7, 1635-1645 (1988).
23. Shannon, K.M. et al. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. New Engl. J.Med. 330, 597-601 (1994).
24. ras. Blood 84, 3435-3439 (1994).
25. Pierce, J.H. & Aaronson, S.A. Myeloid cell transformation by ras-containing murine sarcoma viruses. Mol. Cell. Biol. 5, 667-674 (1985).
26. Kahn, P. et al. v-erbA cooperates with sarcoma oncogenes in leukemic cell transformation. Cell 45, 349-356 (1986).
27. Bollag, G. & McCormick, F. Differential regulation of rasGAP and neurofibromatosis gene product activities. Nature 351, 576-579 (1991).
28. Emanuel, P.D., Bates, L.J., Castleberry, R.P., Gualtieri, R.J. & Zuckerman, K.S. Seletive hypersensitivity to granulocyte-macrophage colony stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood 77, 925-929 (1991).
29. Freedman, M.H. at al. Central role of tumor necrosis factor, GM-CSF, and interleukin 1 in the pathogenesis of juvenile chronic myelogenous leukemia. Br. J. Haemat. 80, 40-48 (1992).
30. Brannan, C. et al. Targeted disruption of the neurofibromatosis, type 1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev. 8, 1019-1029 (1994).
31. Johnson, M.R. et al. Neurofibromin can inhibit Ras-dependent growth by a mechanism independent of its GTPase-accelerating function. Mol. Cell. Biol. 14, 641-645 (1994).
32. Marshall, C.J. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80, 179-185 (1995).
33. Neubauer, A., Shannon, K.M. & Liu, E. Mutations of the ras proto-oncogenes in childhood monosomy 7. Blood 77, 594-598 (1991).
34. Miyauchi, J. et al. Mutations of the N-ras gene in juvenile chronic myelogenous leukemia. Blood 83, 2248-2254 (1994).
35. Burgering, B.M., de Vries-Smits, A.M., Medema, R.H., van Weeren, P.C., Tertoolen, L.G. & Bos, J.L. Epidermal growth factor induces phosphorylation of extracellular signal-regulated kinase 2 via multiple pathways. Mol. Cell Biol. 13, 7248-7256 (1993).
36. Lanfrancone, L. et al. Overexpression of Shc proteins potentiates the proliferative response to the granulocyte-macrophage colony-stimulating factor and recruitment of Grb2/SOS and Grb2/p140 complexes to the β receptor subunit. Oncogene 10, 907-917 (1995).
37. ras·GTP in response to stimulation with epidermal growth factor and oncogene products with tyrosine kinase activity. Proc. Natl. Acad. Sci. USA 87, 7926-7929 (1990).
38. Mui, A.L.-F., Miyajima, A. Interleukin-3 and granulocyte-macrophage colony-stimulating factor receptor signal transduction. Proc. Soc. Exp. Biol. Med. 206 284-288 (1994).
39. Johnson, G.R., Gonda, T.J., Metcalf, D., Hariharan, K. & Cory, S. A lethal myeloproliferative syndrome in mice transplanted with bone marrow cells infected with a retrovirus expressing granulocyte-macrophage colony stimulating factor. EMBO J. 8, 441-448 (1989).
40. Lang, R. et al. Transgenic mice expressing a hematopoietic growth factor gene (GM-CSF) develop accumulations of macrophages, blindness, and a fatal syndrome of tissue damage. Cell 51, 675-686. (1987).
41. Kaneko, Y. at al. Chromosome patterns in juvenile chronic myelogenous leukemia, myelodysplastic syndrome, and acute leukemia associated with neurofibromatosis. Leukemia 3, 36-41 (1989).
42. Vogel, K.S., Brannan, C.I., Jenkins, N.A., Copeland, N.G. & Parada, L.F. Loss of neurofibromin results in neurotrophin-independent survival of embryonic sensory and sympathetic neurons. Cell 82, 733-742 (1995).
43. Gibbs, J.B., Ollif, A. & Kohl, N.E. Farnesyltransferase inhibitor: Ras research yields a potential cancer therapeutic. Cell 77, 175-178 (1994).
44. ras upon T-cell activation. Nature 348, 719-723 (1990).